Search Results - "Neijt, J.P."

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study by Taal, B G, Audisio, R A, Bleiberg, H, Blijham, G H, Neijt, J P, Veenhof, C H, Duez, N, Sahmoud, T

“…Based on a recent pharmacokinetic study suggesting that high biliary levels of mitomycin C (MMC) may be achieved as a result of an entero-hepatic recycling…”
Get more information

A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy by van Bommel, P F, van Lindert, A C, Kock, H C, Leers, W H, Neijt, J P

“…Several prognostic factors in stages I B and II A cervical carcinoma have been widely studied to define groups of patients with a poor prognosis. Most of these…”
Get more information

Ovarian cancer: Progress in chemotherapy by Neijt, J.P.

Get full text

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer : a new standard of care? by DU BOIS, A, NEIJT, J. P, THIGPEN, J. T

“…Cisplatin 75 mg/m2 plus paclitaxel 135 mg/m2 administered over 24 hours have been established as the standard treatment for advanced ovarian cancer. This…”
Get full text

Phase II study of gemcitabine in ovarian cancer by Minckwitz, G. von, Bauknecht, T., Visseren-Grul, C. M., Neijt, J. P.

“…This phase II study evaluated the response rate and toxicity of single-agent gemcitabine in 40 women with epithelial ovarian cancer, previously treated with…”
Get full text

Ovarian cancer : should we be managing patients with good and bad prognostic factors in the same manner? by EISENHAUER, E. A, GORE, M, NEIJT, J. P

“…There are only rare circumstances where knowledge of a patient's prognostic features appropriately guides therapy. The last few years a plethora of studies…”
Get full text

A new standard of care for treatment of ovarian cancer by Piccart, M.J, Du Bois, A, Gore, M.E, Neijt, J.P, Pecorelli, S, Pujade-Lauraine, E

Get full text

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer by Neijt, J P, ten Bokkel Huinink, W W, van der Burg, M E, van Oosterom, A T, Willemse, P H, Vermorken, J B, van Lindert, A C, Heintz, A P, Aartsen, E, van Lent, M

“…In two studies initiated in 1979 and 1981, 377 patients were treated for advanced epithelial ovarian cancer. In the first study patients were randomly assigned…”
Get more information

Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study by Wagenaar, H.C., Pecorelli, S., Mangioni, C., van der Burg, M.E.L., Rotmensz, N., Anastasopoulou, A., Zola, P., Veenhof, C.H.N., Lacave, A.J., Neijt, J.P., van Oosterom, A.T., Einhorn, N., Vermorken, J.B.

“…The aim of this study was to investigate the tumour response rate and toxicity of a combination chemotherapy consisting of mitomycin-C and cisplatin in…”
Get full text

Approximate inference for medical diagnosis by Wiegerinck, W.A.J.J., Kappen, H.J., ter Braak, E.W.M.T., ter Burg, W.J.P.P., Nijman, M.J., O, Y.L., Neijt, J.P.

“…Computer-based diagnostic decision support systems (DSSs) will play an increasingly important role in health care. Due to the inherent probabilistic nature of…”
Get full text

Neurotoxic side-effects of cisplatin by Harmers, F P, Gispen, W H, Neijt, J P

Get more information

Ovarian cancer—New insights into systemic therapy by Neijt, J.P.

Get full text

Treatment of advanced ovarian cancer: 10 years of experience by Neijt, J P

“…Although the majority of the patients with advanced ovarian cancer will die of the disease, optimism is justified in view of the improved results of surgery…”
Get more information

Advanced epithelial ovarian cancer: 1993 consensus statements by Allen, D G, Baak, J, Belpomme, D, Berek, J S, Bertelsen, K, ten Bokkel Huinink, W W, van der Burg, M E, Calvert, A H, Conte, P F, Dauplat, J

“…Over the last few days of a 5-day international workshop held in June 1993, a group of specialists in the field of advanced epithelial ovarian cancer tried to…”
Get more information

Systemic treatment in disseminated endometrial cancer by Neijt, J P

“…Both hormonal agents and chemotherapy are of value in the treatment of selected patients with endometrial cancer. In unselected patients with advanced disease…”
Get more information

Interval Cytoreduction in Ovarian Cancer by Kehoe, S, Shafi, M, Luesley, D

“…To the Editor: The article by van der Burg et al. (March 9 issue) 1 on debulking surgery after induction chemotherapy raises some important issues. The authors…”
Get full text

Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence by Gerritsen van der Hoop, R, Hamers, F P, Neijt, J P, Veldman, H, Gispen, W H, Jennekens, F G

“…Prolonged administration of the anti-tumor agent cisplatin may cause a neuropathy in patients. In an animal model, too, neurotoxicity, as evidenced by a…”
Get more information

Upregulation of B50/GAP-43 protein mRNA in rat dorsal root ganglia during cisplatin intoxication by Hamers, F.P.T., Plantinga, L.-C., Verhaagen, J., Neijt, J.P., Gispen, W.-H.

“…Expression of the growth‐associated protein B50 (GAP‐43) mRNA in dorsal root ganglia (DRG) of rats was studied by in situ hybridization. In response to…”
Get full text

Org.2766 protects from cisplatin-induced neurotoxicity in rats by de Koning, P, Neijt, J P, Jennekens, F G, Gispen, W H

“…One of the side-effects of the cytotoxic drug, cisplatin, is its neurotoxicity. In rats this neurotoxicity can be measured as a slowing of the H-reflex-related…”
Get more information

Ovarian cancer treatment: time for some hard thinking by Neijt, J P

Get more information